Jyoti Malhotra,

Medical oncologist Jyoti Malhotra, M.D., M.P.H., centers her philosophy of care on learning as much as possible about each patient — what is important to them, the challenges they face, and the therapeutic approach they want to take — as well as the details of their disease. She provides care to patients with lung cancer and thoracic tumors as well as to patients with refractory solid tumors as part of phase I/Early Therapeutics program.

In her capacity as director of thoracic medical oncology at City of Hope Orange County, she is excited about offering patients an expansive slate of early-phase clinical trials to offer more people access to new therapies. Dr. Malhotra’s expertise is in Experimental Therapeutics and she has led multiple phase I trials investigating novel agents and combinations for cancer therapy including first-in-human trials. She aims to bring together advances in precision medicine, which targets treatment to the molecular and genetic characteristics of each tumor and immunotherapy, which harnesses the body’s natural defenses to fight cancer. Dr. Malhotra has led seven investigator-initiated clinical trials as well as served as institutional PI on more than 50 trials. She has authored more than 100 publications, book chapters, and abstracts. Dr Malhotra is a member of several national committees including the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer and the Southwest Oncology Group Thoracic Committee.

Dr. Malhotra earned her medical degree from Maulana Azad Medical College at the University of Delhi in India, and then a master’s from the Bloomberg School of Public Health at Johns Hopkins University. She was an internal medicine resident at Georgetown University/Washington Hospital Center and an oncology/hematology fellow at Mount Sinai Medical Center in New York. Her previous appointments were at Memorial Sloan Kettering Cancer Center, Mount Sinai, and Rutgers Cancer Institute of New Jersey, where she was leader of the Phase I/Investigational Therapeutics program.